Watson Receives FDA Approval for Generic DuoNeb(R)

WatsonPharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceuticalcompany, announced today that it has received final approval from theUnited States (U.S.) Food and Drug Administration (FDA) on its AbbreviatedNew Drug Application (ANDA) for Ipratropium Bromide and Albuterol SulfateInhalation Solution in the 0.5 mg/3 mg strength.

Watson's Ipratropium Bromide and Albuterol Sulfate product is thegeneric equivalent to Dey, L.P.'s DuoNeb(R), which is indicated for thetreatment of bronchospasm associated with chronic obstructive pulmonarydisease (COPD) in patients requiring more than one bronchodilator. For the12 months ending September 2007, DuoNeb(R) and its generic equivalents hadtotal U.S. sales of approximately $265 million, according to IMS Healthdata. Watson intends to launch its Ipratropium Bromide and AlbuterolSulfate product immediately.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leadingspecialty pharmaceutical company that develops, manufactures, markets,sells and distributes brand and generic pharmaceutical products. Watsonpursues a growth strategy combining internal product development, strategicalliances and collaborations and synergistic acquisitions of products andbusinesses. For press releases and other company information, visit WatsonPharmaceuticals' Web site at http://www.watsonpharm.com.

Forward-Looking Statement

Any statements contained in this press release that refer to futureevents or other non-historical facts are forward-looking statements thatreflect Watson's current perspective of existing trends and information asof the date of this release. Except as expressly required by law, Watsondisclaims any intent or obligation to update these forward-lookingstatements. Actual results may differ materially from Watson's currentexpectations depending upon a number of factors affecting Watson'sbusiness. These factors include, among others, the impact of competitiveproducts and pricing; market acceptance of and continued demand forWatson's products; difficulties or delays in manufacturing; and other risksand uncertainties detailed in Watson's periodic public filings with theSecurities and Exchange Commission, including but not limited to Watson'sAnnual Report on Form 10-K for the year ended December 31, 2006.